2019/12/29: 最近进展–>Leronlimab用于转移性乳腺癌 Leronlimab promising for metastatic breast cancer
2019/12/28: 最近进展–>FDA批准trastuzumab deruxtecan用于HER2阳性乳腺癌 FDA approved trastuzumab deruxtecan in HER2-positive breast cancer
2019/12/23: 最近进展–>Niraparib 用于新诊断的卵巢癌 Niraparib in newly diagnosed advanced ovarian cancer
2019/12/22: 最近进展–>奥拉帕尼加上贝伐单抗维持治疗改善晚期卵巢癌无进展生存期 Addition of olaparib to maintenance bevacizumab increased PFS in advanced ovarian cancer
2019/12/21: 最近进展–>Veliparib加化疗并维持veliparib单药治疗延长卵巢癌的无进展生存期 Incorporation of Veliparib extends PFS in high-grade serous ovarian cancer
2019/12/15: 最近进展–>每周剂量密集化疗无益于上皮性卵巢癌的一线治疗 First-line weekly dose-dense chemotherapy not beneficial to epithelial ovarian cancer
2019/12/14: 最近进展–>Imprime PGG和pembrolizumab用于难治性三阴性乳腺癌患者 Combination of Imprime PGG and pembrolizumab in chemo-refractory triple-negative breast cancer
2019/12/8: 最近进展–>腺病毒基因疗法用于膀胱癌 Gene therapy for bladder cancer
2019/12/7: 最近进展–>Abemaciclib有益于HER2阳性乳腺癌患者 Abemaciclib benefits HER2-positive breast cancer
2019/12/1: 最近进展–>术前化疗免疫疗法可诱导肺癌亚群中较高的病理响应率Neoadjuvant chemoimmunotherapy induced high rates of pathological response in subset of lung cancer patients
2019/11/30: 最近进展–>放射治疗引起的严重口腔粘膜炎的最新有效治疗 Most recent effective therapy for radiation-induced oral mucositis
2019/11/24: 最近进展->阿妥珠单抗（atezolizumab)与贝伐单抗（bevacizumab）的组合可改善肝癌患者的总体生存率 Atezolizumab and bevacizumab combination can improved overall survival in hepatocellular carcinoma
2019/11/23: 最近进展->口服前列腺癌药物relugolix与现有GnRH受体拮抗剂药物相匹配Oral relugolix is non-inferior compared with current available GnRH antagonists
2019/11/17: 最近进展–>CASPIAN临床试验中期分析：Durvalumab改善广泛期小细胞肺癌的生存率 Midterm analysis of CASPLAN trial showed improved analysis in extensive stage small cell lung cancer
2019/11/9: 最近进展–>Margetuximab治疗HER2阳性转移性乳腺癌中期生存数据Survival data on mid-term analysis of Margetuximab in HER2-positive breast cancer
2019/11/2: 最近进展–>Trilaciclib在转移性三阴性乳腺癌的化疗中的应用 Trilaciclib in combination with chemotherapy in triple negative breast cancer
2019/10/27: 最近进展–>FDA将Navicixizumab作为快速通道药物用于反复治疗过的卵巢癌 FDA granted fast track designation for Navicixizumab to be used in heavily treated ovarian cancer
10/26/2019: 最近进展->尼武单抗联合易普利姆玛第一线治疗非小细胞肺癌 Nivolumab plus ipilimumab as first-line non-chemotherapy for NSCLC
10/20/2019: 最近进展->真菌可以促进胰腺癌发生 Fungi may accelerate the development of pancreatic cancer
10/19/2019: 最近进展->Pembrolizumab加lenvatinib联合治疗晚期子宫内膜癌Combination of pembrolizumab and lenvatinib in advanced endometrial cancer
10/13/2019: 最近进展->转移性结直肠癌的三线治疗的发展 Promising development in third-line therapy in metastatic colorectal cancer
10/12/2019: 最近进展->Alpelisib用于雌激素受体阳性晚期乳腺癌 Alpelisib for ER–Positive Advanced Breast Cancer
10/6/2019: 最近进展->乳腺癌：CDK4/6抑制剂耐药后的治疗选择 Breast cancer: Strategy after resistance to CDK4/6 Inhibition
9/29/2019: 最近进展->具有BRAF突变的可切除III期黑色素瘤的术前免疫治疗 Neoadjuvant immunotherapy in BRAF-mutated stage III melanoma
9/28/2019: 最近进展->AXL抑制剂bemcentinib和pembrolizumab在非小细胞肺癌中的疗效 AXL inhibitor and pembrolizumab effective in chemo-refractory non-small cell lung cancer
9/22/2019: 最近进展->术前talazoparib在BRCA突变的可手术乳腺癌中诱导病理完全反应 Neoadjuvant talazoparib induced pathological complete response in operable breast cancer with BRCA mutation
9/21/2019: 最近进展->两项临床试验的5年汇总分析: Nivolumab相比于泰索帝治疗非小细胞肺癌 Pooled analysis from two phase III trials showed survival benefit of Nivoluman versus docetaxel in previously treated non-small cell lung cancer
9/15/2019: 最近进展->新的治疗转移性胰腺癌的药物 A new drug, CPI-613, for metastatic pancreatic cancer
9/14/2019: 最近进展->Pyrotinib联合卡培他滨治疗HER2阳性转移性乳腺癌 Pyrotinib plus capecitabine for metastatic HER-2-positive breast cancer
9/8/2019: 最近进展->可渗透血脑屏障的纳米免疫结合物诱导胶质母细胞瘤的局部免疫应答 Nano particles carrying checkpoint inhibitors induce brain immune response for glioma
9/7/2019: 最近进展–>组蛋白去乙酰化酶抑制剂abexinostat和pembrolizumab在多种实体肿瘤中的数据 Phase Ib data about combination of histone deacetylase inhibitor abexinostat and pembrolizumab in solid tumors
9/1/2019: 最近进展–>Selinexor:难治性多发性骨髓瘤的新药Selienxor: A promising new drug for refractory multiple myeloma
8/31/2019: 最近进展–>Lynch综合征的症致病性基因，年龄和性别相对于癌症风险Cancer risk by pathogenetic mismatch repair genes, gender and age in Lynch syndrome
8/25/2019: 最近进展–>PARP抑制剂/化疗组合治疗复发性小细胞肺癌 PARP inhibitor and chemotherapy for recurrent small cell lung cancer
8/24/2019: 最近进展–>DNA修复抑制剂加放化疗为对胰腺癌的影响 DNA repair inhibitor plus chemoradiation for locally advanced pancreatic cancer
8/18/2019: 最近进展–>一种新的输送系统可将药物输送到大脑 A new delivery system that carries drugs to the brain
8/17/2019: 最近进展–>增加遗传性胰腺癌风险的新基因突变 Identification of a new hereditary pancreatic cancer risk mutation
8/4/2019: 最近进展–>第一个针对KRAS的活性癌症药物 First time target drug against KRAS mutation showed activity
8/3/2019: 最近进展–>Pembrolizumab与化疗结合用于手术前乳腺癌的3期研究Pembrolizuman and chemotherapy combination in triple negative breast cancer reported to be successful
7/28/2019: 最近进展–>长期使用邻苯二甲酸酯配制的药物与乳腺癌的风 险Phthlate exposure and breast cancer risk
7/27/2019: 最近进展–>新的抗癌免疫疗法抑制纤维化并增强卵巢癌和胰腺癌的化学敏感性 New anticancer immunotherapy inhibits fibrosis and enhances chemosensitivity in ovarian and pancreatic cancer
7/21/2019: 最近进展–>三药联用靶向治疗可改善有BRAF突变的晚期结直肠癌的生存率Triple-targeted therapy improves survival in advanced colorectal cancer with BRAF mutation
7/20/2019: 最近进展–>一个早期发育基因的表达阻止了免疫系统识别和攻击癌细胞 Activation of an embryonic gene protects cancer from recognition by immune system
7/14/2019: 最近进展–>Durvalumab在中期分析中提高了广泛性小细胞肺癌总生存期 Durvalumab was shown to raise overall survival in extensive stage small cell lung cancer in mid-term analysis
7/13/2019: 最近进展–>普通感冒病毒用于治疗膀胱癌 A common cold virus used in treating bladder cancer
7/7/2019: 最近进展–>肥胖超过吸烟成为导致四种不同类型癌症的主要因素 Obesity overtakes smoking as the leading cause of four types of cancer
7/6/2019: 最近进展–>NovoTTF-100L加上化学疗法被FDA批准用于治疗恶性胸膜间皮瘤 NovoTTF-100L plus chemotherapy has been approved by FDA for malignant pleural mesothelioma
6/30/2019: 最近进展–>术前厄洛替尼治疗局部晚期非小细胞肺癌的效果Neoadjuvant erlotinib versus chemotherapy in Stage IIIAN2 NSCLC
6/29/2019: 最近进展–>尿液检测可以提前五年诊断前列腺癌 A simple urine test can diagnose prostate cancer five years earlier
6/23/2019: 最近进展–>软海绵素人工合成的突破推动了一种有效的抗癌剂 Break through in total synthesis of halichondrin heralds a novel anti-cancer drug
6/22/2019: 最近进展–>控制烟草措施使加利福尼亚州的肺癌死亡人数减少了28％Tobacco control reduces lung cancer deaths in California by 28%
6/16/2019: 最近进展–>Erdafitinib为美国食品和药物管理局批准用于局部晚期或转移性尿路上皮癌 Erdafitinib was approved by FDA for locally advanced or metastatic urothelial cell cancer
6/15/2019: 最近进展–>生物标志物预测哪些胰腺囊肿可能变成癌性囊肿 Biomarkers used to predict which pancreatic cysts may become cancerous
6/9/2019: 最近进展–>AKT抑制剂capivasertib加上fulvestrant有利于芳香酶抑制剂治疗失败后乳腺癌 AKT inhibitor Capivasertib plus fulvestrant benefits metastatic breast cancer patients after progression on aromatase inhibitor
6/8/2019: 最近进展–>Pembrolizumab对非肌肉浸润性耐受BCG的高风险膀胱癌有效 Pembrolizumub for high-risk non-muscle invasive bladder cancer refractory to BCG
6/2/2019: 最近进展–>切除原发病灶改善HER2阳性IV期乳腺癌的生存 Surgery improves survival in HER2-positive metastatic breast cancer women
6/1/2019: 最近进展–>十分有希望的胶质母细胞瘤自体疫苗 A promising autologous vaccine against glioblastoma
5/26/2019: 最近进展–>抗TIM-3抗体 作为单一疗法和抗PD-L1抗体的组合耐受良好 Anti-TIM-3 antibody was well tolerated as a single agent or in combination with PD-L1 blockade
5/25/2019: 最近进展–>Tocilizumab用于难治的由阻断PD-1免疫治疗所引起的不良反应 Tocilizumab effective for PD-1 blockade-related adverse effects
5/19/2019: 最近进展–>局部晚期前列腺癌切除术前多药雄激素剥夺疗法提高响应率 Intense neoadjuvant androgen deprivation for locally advanced prostate cancer
5/12/2019: 最近进展–>阻断胰腺星状细胞分泌的蛋白质以治疗胰腺癌 Targeting protein secreted by pancreatic stellete cells to treat pancreatic cancer
5/11/2019: 最近进展–>Savolitinib和osimertinib的组合在EGFR突变的非小细胞肺癌患者 Savolitinib and osimertinib combination may benefit EGFR mutant and MET-amplified NSCLC patients
5/5/2019: 最近进展–>如何处理乳腺癌局部复发的问题：Memorial Sloane-Kettering 癌症中心乳腺癌外科主任Morrow医生 How to mangae local recurrence in breast cancer: presented by Dr. Morrow, chief of breast cancer service at MSKCC
5/4/2019: 最近进展–>Darolutamide延长非转移性前列腺癌患者的无转移生存期 Darolutamide prolonged metastasis-free survival in castration-resistant prostate cancer
4/28/2019: 最近进展–>逆转黑色素瘤对免疫疗法的抵抗力 Entinostat, a histone deacetylase inhibitor, may reverse melanoma resistance to immunotherapy
4/27/2019: 最近进展–>更多数据显示延长内分泌治疗的益处 More data regarding the benefit of extended endocrine therapy
4/21/2019: 最近进展–>放射性配体疗法对转移性前列腺癌的疗效 Radioligand has activity in metastatic prostate cancer
4/20/2019: 最近进展–>Denosumab辅助治疗有利于激素受体阳性的绝经后乳腺癌患者 Advantage of adjuvant denosumab for estrogen-receptor positive postmenopausal breast cancer
4/14/2019: 最近进展–>粪便移植可以帮助黑色素瘤患者响应免疫治疗 Fecal transplant may help melanoma patients on immunotherapy
4/13/2019: 最近进展–>人乳头瘤病毒（HPV）治疗性疫苗Tipapkinogen Sovacivec对宫颈上皮内瘤变的有效性和安全性 Safety and efficacy of therapeutic HPV vaccine Tipapkinogen sovacivec in treating cervical intraepithelial neoplasia
4/7/2019: 最近进展–>抑制外来体的PD-L1会诱导抗肿瘤免疫 Inhibition of exosomal PD-L1 leads to tumor suppression
4/6/2019: 最近进展–>BRAF和MEK靶向治疗胆管癌 Target therapy with BRAF and MEK inhibitors may benefit biliary tract cancer
3/31/2019: 最近进展–>免疫治疗用于晚期难治性结直肠癌 Combination of Durvalumab and tremelimumab for refractory colorectal cancer
3/30/2019: 最近进展–>肿瘤相关免疫细胞如何阻碍治疗胰腺癌的化疗药物吉西他滨 How tumor-associated immune cells hinder gemcitabine in Pancreatic Cancer
3/24/2019: 最近进展–>药物海绵可以减少癌症治疗的副作用 (3/24/2019)Drug sponge may decrease side effects of cancer therapy
3/23/2019: 最近进展–>病理性完全缓解的乳腺癌患者可以在手术后避免化疗? 芸萃分析的结果 Breast cancer patients who achieved pathologic complete response may not need post-operative chemo
3/17/2019: 最近进展–>Pembrolizumab / Axitinib联合治疗相比于舒尼替尼可改善肾癌患者的治疗效果 Pembrolizumab / Axitinib combination therapy may improve survival in patients with renal cell carcinoma compared with sunitinib
3/16/2019: 最近进展–>PET扫描识别可避免化疗的乳腺癌患者 PET scan may detect those women who may avoid chemotherapy
3/10/2019: 最近进展–>如何改变对免疫治疗缺乏反应的肿瘤 How to increase response to immunotherapy in otherwise “cold” cancer
3/9/2019: 最近进展–>Capivasertib对AKT突变的癌症有效 Capivasertib is effective in ALK-mutated tumors
3/3/2019: 实体肿瘤–>乳腺癌–>三阴性–>病例讨论
3/3/2019: 最近进展–>狄诺塞麦（Denosumab）加上芳香酶抑制剂可以改善雌激素受体阳性乳腺癌的预后 Denosumab plus aromatase inhibitors improves prognosis in estrogen receptor-positive breast cancer
3/2/2019: 最近进展–>术前单剂抗PD-1治疗可预测黑色素瘤的预后 Single dose of pre-operative pembrolizumab can predict outcome in melanoma patients
2/8/2019: 最近进展–>Avapritinib有可能改变胃肠道间质瘤治疗的常规 Potential practice change for Avapritinib in the treatment of gastrointestinal stromal tumor (GIST)
2/3/2019: 最近进展–>Brigatinib与克里唑蒂尼在ALK阳性非小细胞肺癌中的应用Comparison of brigatinib and crizotinib in ALK-positive non-small cell lung cancer
2/2/2019: 最近进展–>身体如何保护播散的乳腺癌细胞及动物试验如何预防它 How body protects breast cancer cells and animal studies how to prevent it
1/26/2019: 最近进展–>术前化疗与首先减瘤手术用于卵巢/输卵管癌的比较 Comparison of neoadjuvant chemotherapy and upfront debulking surgery in advanced tubo-ovarian cancer
1/20/2019: 最近进展–>Margetuximab加Pembrolizumab对晚期HER2 阳性胃癌的抗肿瘤活性 Combination of Margetuximab and Pembrolizumab showed activity in advanced HER2-positive gastric cancer
1/19/2019: 最近进展–>BRAF突变的结直肠癌对治疗的挑战 Challenges from BRAF-mutated colorectal cancer
1/13/2019: 最近进展–>大剂量高精度放射治疗提高一些”无法治愈”患者的生存率 High dose of radiation improved survival in cancer patient with oilgomets
1/12/2019: 最近进展–>HDAC抑制剂可能克服晚期乳腺癌对内分泌治疗的耐药性 HDAC inhibitors may overcome resistance to endocrine therapy in advanced breast cancer
1/6/2019: 最近进展–>索拉非尼和拓扑替康对耐铂类卵巢癌有效 Sorafenib and topotecan effective in platinum-resistant ovarian cancer
1/5/2019: 最近进展–>第一个术前免疫疗法用于结肠癌的试验 First clinical trial about preoperative immunotherapy in colon cancer